Literature DB >> 28296139

Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS).

John G F Cleland1,2, John R Teerlink3, Beth A Davison4, Ahmad Shoaib1, Marco Metra5, Stefanie Senger4, Olga Milo4, Gad Cotter4, Robert C Bourge6, John D Parker7, Guillaume Jondeau8, Henry Krum9, Christopher M O'Connor10, Guillermo Torre-Amione11, Dirk J van Veldhuisen12, John J V McMurray13.   

Abstract

OBJECTIVE: Plasma concentrations of B-type natriuretic peptide (BNP) and troponin are often measured for diagnostic purposes when patients are admitted with heart failure, but their prognostic value when measured soon after admission is uncertain. We aimed to investigate the added prognostic value of admission measurements of BNP and troponins in patients with acute heart failure. METHODS AND
RESULTS: Multivariable prognostic models for death or any worsening heart failure (WHF) or rehospitalization for WHF by 30 days, 30-day death or rehospitalization for WHF, and 90-day mortality were constructed using baseline data from the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS) including BNP and troponin I. Of 1347 patients, the median (interquartile range) value of BNP was 422 (156-945) pg/mL and 855 (63%) had measurable troponin I. By 30 days, 432 patients had died or experienced WHF. Clinical variables had only moderate predictive performance that was not substantially improved by BNP or troponin I (c-indices 0.6528 and 0.6595, respectively). By 30 days, 150 patients died or were rehospitalized for WHF. The c-index using clinical variables (0.6855) was not improved by adding biomarkers. By 90 days, 135 patients had died. The c-index for mortality was somewhat better than for composite outcomes (0.7394) but improved little with biomarkers (0.7461).
CONCLUSION: Routine clinical data recorded at the time of admission in patients with acute heart failure are poor at predicting recurrent admissions but somewhat better at predicting mortality. Neither BNP nor troponin measured at admission improved predictions; measurement closer to discharge, or of other novel biomarkers, might perform differently.
© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.

Entities:  

Keywords:  Acute heart failure; Biomarkers; Prognosis; Statistical models

Mesh:

Substances:

Year:  2017        PMID: 28296139     DOI: 10.1002/ejhf.786

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  11 in total

1.  Red cell distribution width and prognosis in acute heart failure: ready for prime time!

Authors:  Roger Hullin; Nicolas Barras; Tamila Abdurashidova; Pierre Monney; Julien Regamey
Journal:  Intern Emerg Med       Date:  2018-12-13       Impact factor: 3.397

2.  Combined use of lung ultrasound, B-type natriuretic peptide, and echocardiography for outcome prediction in patients with acute HFrEF and HFpEF.

Authors:  Alberto Palazzuoli; Gaetano Ruocco; Matteo Beltrami; Ranuccio Nuti; John G Cleland
Journal:  Clin Res Cardiol       Date:  2018-03-12       Impact factor: 5.460

3.  Outcome of hospitalised heart failure in Japan and the United Kingdom stratified by plasma N-terminal pro-B-type natriuretic peptide.

Authors:  Yasuyuki Shiraishi; Toshiyuki Nagai; Shun Kohsaka; Ayumi Goda; Yuji Nagatomo; Atsushi Mizuno; Takashi Kohno; Alan Rigby; Keiichi Fukuda; Tsutomu Yoshikawa; Andrew L Clark; John G F Cleland
Journal:  Clin Res Cardiol       Date:  2018-05-21       Impact factor: 5.460

4.  Lack of correlation between different congestion markers in acute decompensated heart failure.

Authors:  Svenja Haag; Alexander Jobs; Thomas Stiermaier; Carlo-Federico Fichera; Christina Paitazoglou; Ingo Eitel; Steffen Desch; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2022-06-01       Impact factor: 5.460

5.  Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?

Authors:  Gregory J Wehner; Linyuan Jing; Christopher M Haggerty; Jonathan D Suever; Joseph B Leader; Dustin N Hartzel; H Lester Kirchner; Joseph N A Manus; Nick James; Zina Ayar; Patrick Gladding; Christopher W Good; John G F Cleland; Brandon K Fornwalt
Journal:  Eur Heart J       Date:  2020-03-21       Impact factor: 29.983

6.  The Association Between Novel Biomarkers and 1-Year Readmission or Mortality After Cardiac Surgery.

Authors:  Jeffrey P Jacobs; Shama S Alam; Sherry L Owens; Devin M Parker; Michael Rezaee; Donald S Likosky; David M Shahian; Marshall L Jacobs; Heather Thiessen-Philbrook; Moritz Wyler von Ballmoos; Kevin Lobdell; Todd MacKenzie; Allen D Everett; Chirag R Parikh; Jeremiah R Brown
Journal:  Ann Thorac Surg       Date:  2018-06-01       Impact factor: 4.330

7.  Pharmacological interventions for heart failure in people with chronic kidney disease.

Authors:  Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani
Journal:  Cochrane Database Syst Rev       Date:  2020-02-27

Review 8.  Highlights in heart failure.

Authors:  Daniela Tomasoni; Marianna Adamo; Carlo Mario Lombardi; Marco Metra
Journal:  ESC Heart Fail       Date:  2019-12

9.  Comparison of Troponin Elevation, Prior Myocardial Infarction, and Chest Pain in Acute Ischemic Heart Failure.

Authors:  Cassandra Freitas; Xuesong Wang; Yin Ge; Heather J Ross; Peter C Austin; Peter S Pang; Dennis T Ko; Michael E Farkouh; Therese A Stukel; John J V McMurray; Douglas S Lee
Journal:  CJC Open       Date:  2020-02-24

10.  The Added Value of In-Hospital Tracking of the Efficacy of Decongestion Therapy and Prognostic Value of a Wearable Thoracic Impedance Sensor in Acutely Decompensated Heart Failure With Volume Overload: Prospective Cohort Study.

Authors:  Christophe J P Smeets; Seulki Lee; Willemijn Groenendaal; Gabriel Squillace; Julie Vranken; Hélène De Cannière; Chris Van Hoof; Lars Grieten; Wilfried Mullens; Petra Nijst; Pieter M Vandervoort
Journal:  JMIR Cardio       Date:  2020-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.